Orthofix Medical (OFIX) EBIT (2010 - 2026)

Orthofix Medical has disclosed EBIT across 17 years of filings, most recently posting -$14.4 million for Q1 2026.

• Quarterly EBIT rose 70.46% year-over-year to -$14.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$47.0 million (up 54.88% YoY) and the FY2025 annual result came in at -$81.4 million, up 3.77% from the prior year.
• EBIT slipped to -$14.4 million in Q1 2026, from $494000.0 in the prior quarter.
• Over five years, EBIT peaked at $6.6 million in Q2 2022 and troughed at -$59.7 million in Q1 2023.
• A 5-year average of -$19.0 million and a median of -$17.0 million in 2025 frame the typical range for EBIT.
• Annual changes were most pronounced in 2023 — EBIT sank 1840.03% — and 2025, when it jumped 104.3%.
• Tracing OFIX's EBIT over 5 years: stood at -$1.5 million in 2022, then sank by 1125.9% to -$18.3 million in 2023, then surged by 37.34% to -$11.5 million in 2024, then soared by 104.3% to $494000.0 in 2025, then sank by 3022.27% to -$14.4 million in 2026.
• Business Quant data shows OFIX's EBIT at -$14.4 million in Q1 2026, $494000.0 in Q4 2025, and -$17.0 million in Q3 2025.